azacitidine
Selected indexed studies
- Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. (N Engl J Med, 2022) [PMID:35443108]
- Azacitidine. (IARC Monogr Eval Carcinog Risks Hum, 1990) [PMID:1705587]
- Azacitidine-induced pneumonitis and literature review. (BMJ Case Rep, 2020) [PMID:33122228]
_Worker-drafted node — pending editorial review._
Connections
azacitidine is a side effect of
Sources
- Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. (2022) pubmed
- Azacitidine. (1990) pubmed
- Azacitidine-induced pneumonitis and literature review. (2020) pubmed
- Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. (2022) pubmed
- Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. (2022) pubmed
- 5-Azacytidine/Azacitidine. (2010) pubmed
- Azacitidine: in myelodysplastic syndromes. (2005) pubmed
- Azacitidine-induced hyperglycaemia. (2019) pubmed
- Azacitidine. (2005) pubmed
- Azacitidine. (2005) pubmed